Monograph
C09BA08 - Cilazapril and Diuretics |
Propably not porphyrinogenic |
PNP |
Rationale
Cilazapril: No evidence of significant CYP-dependent metabolism. Occasional observations of tolerance. Two references stating (probable) non-porphyrinogenicity. Hydrochlorthiazide: Not metabolised. Probably no CYP-affinity. Clinical experience of non-porphyrinogenicity. Conflicting evidence.
Chemical description
Cilazapril: Hydrolyzed to cilazaprilate, a long term ACE- inhibitor. Excreted (90%) in unchanged form by the kidneys. Hydrochlorthiazide: thiazide diuretic. Eliminated in urine in unchanged form. No observations of CYP interaction. Cilazapril: Swedish experience (n=2): safe. South African list: use with care. French list: authorized. Hydrochlorthiazide: South African list: use. French list: authorized. Australian list: unsafe associated with attacks. Thunell, patient report (n=1): tolerated. Andersson, patient reports (n=10): tolerated. Martindale: Hydrochlorthiazide has been associated with acute attacks of porphyria and is considred unsafe in porphyric patients. EPI-list: sulfonamides on the unsafe list.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
Poland
Serbia© NAPOS 2024